The peptide has also shown that it is a candidate in the treatment of periodontal disease when it was given to a rodent test subject that had periodontitis
As of 2026, no registered Phase I or Phase II trials for KPV in humans are listed on ClinicalTrials.gov.12 The FDA specifically cited the lack of human exposure data as part of its 2023 categorization decision.8 What this means practically: Efficacy signals from animal models do not automatically translate to human outcomes Long-term safety in human populations has not been established Dosing protocols remain clinical judgment calls rather than evidence-based standards Any patient considering KPV should do so under clinical supervision with baseline inflammatory marker testing These limitations do not invalidate the research
At the default 5 mg / 2 mL reconstitution (2.5 mg/mL concentration), a 0.2 mg dose draws to 8 units on the syringe
Common Mild Reactions Local irritation where the peptide was injected (minor redness or tenderness) Occasional dizziness or fatigue shortly after use Typically mild and short-lived Potential Risks Not FDA-approved for Lyme disease or any other condition Contraindicated in active cancer due to its angiogenesis-promoting properties Should be avoided during pregnancy or breastfeeding Take Precautions with Medical Guidance Since its administered via injection and isnt regulated for Lyme treatment, a professional Lyme disease expert should guide your dosing
Across these studies, patients who fully recovered from COVID-19 without residual symptoms often showed normalization of their gut microbiota [13,17,18,19,20] (Figure 1)
